Fig. 4

Activation of FLT3-TAZ signaling correlates with less favorable prognosis in BP-CML. A Immunoblotting analysis of FLT3-pSTAT3-TAZ components and BCR::ABL1 in 27 clinical samples derived from CP-CML patients. BP-CML patient sample 2028 was used as a control for comparing protein expression levels between CP and BP patients. CML prognostic factors such as disease phase, BCR::ABL1/ABL1 (%IS), and blast % are indicated above each patient specimen. B Immunoblotting analysis of 27 clinical samples derived from BP-CML patients. CP-CML patient sample 903 was used as a control for comparing protein expression levels between CP and BP patients. C and D Immunoblotting analysis of paired serial samples from individual patients. CHR, complete hematologic response; MyBC, myeloid blast crisis; NEL, no evidence of leukemia. E Pie chart showing the co-expression patterns between FLT3, pSTAT3, and TAZ proteins in BP-CML patients (n = 27). F and G Clinical relevance of FLT3 expression level and prognostic factors for CML, including BCR::ABL1/ABL1 ratio (IS%) (F) and blast percentage (G), in BP-CML patients. FLT3⁻, n = 13; FLT3.⁺, n = 14. All p-values were calculated using Student’s t-test and error bars are means ± SD. A p-value of less than 0.05 indicates a statistical difference. **p < 0.01